Top Page
Outlook Therapeutics
(NASDAQ:OTLK)
Outlook Therapeutics (OTLK) vs. SPDR S&P 500 ETF (SPY)
Outlook Therapeutics Business Overview & Revenue Model
Outlook Therapeutics Earnings Call Summary
Outlook Therapeutics Financial Statement Overview
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 205.53K | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.21M | 657.21K | -113.86K | -44.19K | -204.69K | -262.14K |
| EBITDA | -60.47M | -63.58M | -72.09M | -57.38M | -64.36M | -51.51M |
| Net Income | -102.86M | -62.42M | -75.37M | -58.98M | -66.05M | -53.16M |
Balance Sheet | ||||||
| Total Assets | 18.24M | 18.58T | 28.82M | 32.30M | 28.53M | 22.81M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 8.08T | 14.93M | 23.39M | 17.40M | 14.48M |
| Total Debt | 36.89M | 247.70B | 29.74M | 35.56M | 10.96M | 11.90M |
| Total Liabilities | 56.79M | 50.77T | 101.90M | 46.74M | 19.79M | 18.20M |
| Stockholders Equity | -38.55T | -32.19T | -73.08M | -14.44M | 8.74M | 4.61M |
Cash Flow | ||||||
| Free Cash Flow | -14.94T | -51.83T | -68.79M | -42.97M | -56.67M | -54.25M |
| Operating Cash Flow | -14.94T | -51.83T | -68.79M | -42.97M | -56.67M | -54.25M |
| Investing Cash Flow | -3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.53T | 44.98T | 60.33M | 48.97M | 59.59M | 56.19M |
Outlook Therapeutics Technical Analysis
Outlook Therapeutics Risk Analysis
Outlook Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $138.91M | 0.57 | 27.20% | ― | ― | 814.20% | |
58 Neutral | $169.44M | -7.27 | -10.35% | ― | -42.62% | ― | |
53 Neutral | $171.09M | -1.36 | -63.41% | ― | -87.59% | 11.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $35.18M | -0.59 | 763.31% | ― | -15.81% | -113.06% | |
42 Neutral | $40.15M | 6.94 | -79.12% | ― | 51.27% | ― | |
41 Neutral | $29.16M | -1.03 | <0.01% | ― | ― | 86.28% |
Outlook Therapeutics Corporate Events
On March 16, 2026, Outlook Therapeutics entered into a Note Purchase Agreement with Atlas Sciences for an unsecured promissory note with an original principal balance of $18.36 million, issued at a discount for $17 million in proceeds, which were used solely to partially repay its existing $33.1 million convertible note with Avondale Capital. After this refinancing step, approximately $10.8 million remained outstanding under the Avondale note, whose maturity was simultaneously extended to December 31, 2026, while the new Atlas note carries interest at prime plus 3%, matures in 15 months, includes quarterly investor redemption rights, and restricts certain financings and liens, underscoring the company’s continued liquidity pressures and substantial doubt about its ability to continue as a going concern.
The transactions highlight Outlook Therapeutics’ ongoing reliance on debt and capital markets to fund development and commercialization of ONS-5010/LYTENAVA amid a constrained cash position and recent regulatory setbacks in the U.S. The company warns that, without substantial additional capital and potential strategic partnerships, it may be unable to meet future debt obligations or sustain operations, raising significant risk for creditors and shareholders.
The most recent analyst rating on (OTLK) stock is a Sell with a $0.40 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
On March 6, 2026, Outlook Therapeutics’ board accepted the resignation of director Dr. Julia Haller, effective March 11, 2026, and voted to reduce the size of the board to nine members upon her departure. Dr. Haller, a Class II director and member of the Nominating and Corporate Governance Committee, stepped down due to new time demands as CEO of Wills Eye Hospital, and the company emphasized that her resignation did not arise from any disagreement over its operations or policies.
Her exit removes an experienced ophthalmology leader from the board, but the orderly nature of the transition and the board’s decision to shrink its size suggest a controlled adjustment in governance rather than a sign of internal conflict. The company and board publicly thanked Dr. Haller for her contributions, underscoring continued goodwill and her stated intention to remain a supporter of Outlook Therapeutics’ efforts to advance therapies for patients with unmet ophthalmic needs.
The most recent analyst rating on (OTLK) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
At its annual meeting held on March 10, 2026, Outlook Therapeutics shareholders elected three Class I directors — Yezan Haddadin, Faisal G. Sukhtian and Kurt J. Hilzinger — to serve on the board until the 2029 annual meeting, reinforcing continuity in the company’s leadership. Investors also ratified KPMG LLP as the independent auditor for the fiscal year ending September 30, 2026, and approved, on a non-binding basis, the compensation of the company’s named executive officers, signaling overall shareholder support for current governance, oversight and pay practices.
The voting turnout represented roughly half of the company’s outstanding common shares, suggesting a moderate level of investor engagement in corporate decisions. Approval of all three proposals is expected to provide stability for Outlook Therapeutics’ board structure and financial reporting framework, while the advisory endorsement of executive pay indicates that, for now, shareholders are broadly aligned with management’s compensation strategy and corporate direction.
The most recent analyst rating on (OTLK) stock is a Hold with a $0.42 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
On March 5, 2026, Outlook Therapeutics reported it had held a Type A meeting with the U.S. Food and Drug Administration to address a December 30, 2025 complete response letter for its biologics license resubmission for ONS-5010/LYTENAVA™, an investigational bevacizumab formulation for wet AMD. The discussion focused on clarifying the FDA’s concerns over substantial evidence of effectiveness, with the company seeking alignment on confirmatory data and the most efficient pathway to potential U.S. approval.
Outlook highlighted that ONS-5010 achieved statistically significant visual acuity gains in its NORSE TWO Phase 3 trial and showed supportive efficacy and safety data from NORSE EIGHT and other studies, with no safety issues flagged by regulators. If ultimately approved in the United States, ONS-5010 would become the first FDA-approved ophthalmic bevacizumab product for retinal indications, backed by a fully domestic manufacturing supply chain, a development that could reshape the treatment landscape for wet AMD and formalize a drug class long used off-label.
The most recent analyst rating on (OTLK) stock is a Sell with a $0.39 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
On February 18, 2026, Outlook Therapeutics received notice from Nasdaq that its common stock had closed below the required $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing standards. The notification does not immediately affect the stock’s listing, but the company has until August 17, 2026, to lift its closing bid price to at least $1.00 for ten consecutive business days or risk potential delisting, prompting management to monitor the share price and evaluate options such as a reverse stock split and possible appeal procedures if needed.
If Outlook Therapeutics fails to regain compliance by the August deadline and does not qualify for or succeed during an additional 180-day grace period, its stock could be delisted from the Nasdaq Capital Market, which may reduce liquidity and complicate capital-raising efforts. The situation underscores the company’s precarious market positioning and highlights the importance for shareholders of the firm’s forthcoming strategic decisions to address the low share price and maintain its Nasdaq listing.
The most recent analyst rating on (OTLK) stock is a Hold with a $0.41 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
On February 11, 2026, Outlook Therapeutics announced it had requested a Type A meeting with the U.S. Food and Drug Administration to address a Complete Response Letter dated December 30, 2025, relating to its resubmitted biologics license application for ONS-5010/LYTENAVA for wet age-related macular degeneration. The letter cited a single deficiency, a purported lack of substantial evidence of effectiveness and a need for additional confirmatory data, a conclusion the company disputes based on prior FDA interactions and the totality of its clinical package.
Outlook Therapeutics emphasized that its BLA is backed by the Phase 3 NORSE TWO trial, which met primary and key secondary visual acuity endpoints at 12 months, and by NORSE EIGHT and other mechanistic, pharmacodynamic and natural history data that it says collectively satisfy the FDA’s substantial evidence standard. While NORSE EIGHT did not meet its primary endpoint at eight weeks, the company highlighted consistent vision gains through 12 weeks, a favorable safety profile comparable to existing anti-VEGF therapies, and argued that an FDA-approved, domestically manufactured bevacizumab for wet AMD could offer a standardized, high-quality alternative to current off-label use, making the outcome of these regulatory discussions significant for patients, prescribers and the U.S. retina market.
The most recent analyst rating on (OTLK) stock is a Sell with a $0.38 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
On December 31, 2025, Outlook Therapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter to its resubmitted biologics license application for ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration, stating it could not approve the application in its current form and again calling for additional confirmatory evidence of efficacy without specifying what form that evidence should take. The setback delays potential U.S. approval despite the company’s reliance on data from its NORSE clinical trial program, including the successful NORSE TWO pivotal study and the NORSE EIGHT non-inferiority trial, and shifts strategic emphasis toward exploring alternative regulatory pathways in the U.S. while expanding commercialization and partnership efforts in Europe and other regions, where LYTENAVA is already authorized and beginning to establish a foothold as a differentiated, on-label bevacizumab option for wet AMD patients.
The most recent analyst rating on (OTLK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.